3D Whole-Brain Imaging Approaches to Study Brain Tumors.

Cancers (Basel)

Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Published: April 2021

Although our understanding of the two-dimensional state of brain tumors has greatly expanded, relatively little is known about their spatial structures. The interactions between tumor cells and the tumor microenvironment (TME) occur in a three-dimensional (3D) space. This volumetric distribution is important for elucidating tumor biology and predicting and monitoring response to therapy. While static 2D imaging modalities have been critical to our understanding of these tumors, studies using 3D imaging modalities are needed to understand how malignant cells co-opt the host brain. Here we summarize the preclinical utility of in vivo imaging using two-photon microscopy in brain tumors and present ex vivo approaches (light-sheet fluorescence microscopy and serial two-photon tomography) and highlight their current and potential utility in neuro-oncology using data from solid tumors or pathological brain as examples.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071100PMC
http://dx.doi.org/10.3390/cancers13081897DOI Listing

Publication Analysis

Top Keywords

brain tumors
12
imaging modalities
8
brain
5
tumors
5
whole-brain imaging
4
imaging approaches
4
approaches study
4
study brain
4
tumors understanding
4
understanding two-dimensional
4

Similar Publications

Background: Bone-invasive Pituitary Neuroendocrine Tumors (BI PitNETs) epitomize an aggressive subtype of pituitary tumors characterized by bone invasion, culminating in extensive skull base bone destruction and fragmentation. This infiltration poses a significant surgical risk due to potential damage to vital nerves and arteries. However, the mechanisms underlying bone invasion caused by PitNETs remain elusive, and effective interventions for PitNET-induced bone invasion are lacking in clinical practice.

View Article and Find Full Text PDF

Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases.

Sci Rep

January 2025

Department of Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei, China.

Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30-40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM.

View Article and Find Full Text PDF

This study investigated the relationship between the frailty index and all-cause and cause-specific mortality in patients with depression. We recruited 2,669 participants with depression from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018 and quantified their frailty status using a 53-item frailty index. Cox proportional hazards models were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI).

View Article and Find Full Text PDF

Overexpression of miR-124 enhances the therapeutic benefit of TMZ treatment in the orthotopic GBM mice model by inhibition of DNA damage repair.

Cell Death Dis

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi Province, China.

Glioblastoma (GBM) is the most common malignant primary brain cancer with poor prognosis due to the resistant to current treatments, including the first-line drug temozolomide (TMZ). Accordingly, it is urgent to clarify the mechanism of chemotherapeutic resistance to improve the survival rate of patients. In the present study, by integrating comprehensive non-coding RNA-seq data from multiple cohorts of GBM patients, we identified that a series of miRNAs are frequently downregulated in GBM patients compared with the control samples.

View Article and Find Full Text PDF

Introduction: Temozolomide (TMZ) is a widely used chemotherapy agent for the treatment of malignant gliomas and other brain tumors. Despite its established therapeutic benefits, there is an ongoing need to understand better its safety profile, particularly in real-world clinical settings. This study aimed to identify critical adverse drug reactions (ADRs) associated with TMZ by utilizing the FDA Adverse Event Reporting System (FAERS) database, thereby providing valuable safety insights for clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!